Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Inf Natalizumab(tysabri) 300mg/15ml Vi## (CDM 5930026) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 9, 2026 , from http://ppman.hank.ai/transparency/procedure/5930026/by-state?code_type=CDM
“Inf Natalizumab(tysabri) 300mg/15ml Vi## (CDM 5930026) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/5930026/by-state?code_type=CDM. Accessed
October 9, 2026 .
“Inf Natalizumab(tysabri) 300mg/15ml Vi## (CDM 5930026) by State,” HANK Price Transparency ,
accessed October 9, 2026 ,
http://ppman.hank.ai/transparency/procedure/5930026/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
5930026 — Inf Natalizumab(tysabri) 300mg/15ml Vi##
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$22,357
National median
$20,825 – $24,856
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 5930026 (CDM), with interquartile range
State Median p25 p75
KS $22,357 $20,825 $24,856